SNTISenti Biosciences, Inc.

Nasdaq sentibio.com


$ 0.33 $ 0.01 (2.89 %)    

Friday, 05-Jul-2024 15:59:51 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 0.3344
$ 0.33
$ 0.00 x 0
$ 0.00 x 0
$ 0.32 - $ 0.33
$ 0.21 - $ 1.09
1,214,252
na
15.28M
$ 2.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-07-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 senti-biosciences-snti-stock-is-up-over-100-whats-happening

Senti Biosciences shares are trading higher by 102.6% during Monday's session. The company was awarded $8 million from the ...

 senti-biosciences-q1-eps-026-up-from-042-yoy

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.26) per share. This is a 38.1 percent increase over losses of ...

 senti-biosciences-q4-2023-gaap-eps-042-misses-028-estimate

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...

 senti-biosciences--said-reducing-its-workforce-by-37-as-part-of-prioritizing-its-investment-in-lead-clinical-program

Senti Biosciences, Inc. (NASDAQ:SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-ge...

 why-is-blood-cancer-focused-senti-biosciences-stock-trading-higher-today

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, a...